Researchers from the University of Arizona presented the discovery of first-in-class dual-specificity tyrosine phosphorylation-regulated kinase 1A/B (DYRK1A/B) proteolysis targeting chimeras (PROTACs) as potential Alzheimer’s disease (AD) therapeutic candidates.